Financial Performance - Revenue for the third quarter reached RMB 163.26 million, a year-on-year increase of 16.34%[2] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 73.00 million, up 13.40% year-on-year[2] - Cumulative revenue from the beginning of the year to the end of the reporting period was RMB 427.26 million, a year-on-year increase of 23.53%[2] - Cumulative net profit attributable to shareholders from the beginning of the year to the end of the reporting period was RMB 197.45 million, up 37.91% year-on-year[2] - Operating income for the first three quarters of 2024 reached 427,255,735.56 yuan, a significant increase from 345,881,895.73 yuan in the same period last year[17] - Net profit for the first three quarters of 2024 was 197,452,784.89 yuan, compared to 143,174,996.17 yuan in the same period last year[19] - Operating profit for the first three quarters of 2024 was 230,234,063.11 yuan, compared to 163,799,376.83 yuan in the same period last year[19] - Net profit attributable to parent company shareholders reached RMB 197,452,784.89, an increase from RMB 143,174,996.17 in the previous year[20] - Basic earnings per share (EPS) increased to RMB 2.4499 from RMB 2.0522 year-over-year[20] R&D Investment - R&D investment for the third quarter was RMB 15.58 million, a year-on-year increase of 52.36%, accounting for 9.55% of revenue[3] - Cumulative R&D investment from the beginning of the year to the end of the reporting period was RMB 41.44 million, up 46.77% year-on-year[3] - R&D expenses increased to 41,435,654.28 yuan, up from 28,231,012.70 yuan in the previous year[19] Cash Flow and Financial Position - Net cash flow from operating activities from the beginning of the year to the end of the reporting period was RMB 216.59 million, a year-on-year increase of 50.64%[2] - Cash flow from operating activities was RMB 216,593,741.59, up from RMB 143,785,401.26 in the same period last year[21] - Cash received from sales of goods and services amounted to RMB 473,853,531.45, compared to RMB 343,288,191.11 in the previous year[21] - Cash outflow from investment activities was RMB 3,639,173,424.43, significantly higher than RMB 40,349,666.82 in the prior year[22] - Cash inflow from financing activities reached RMB 1,820,326,000.00, primarily due to subsidiary minority shareholder investments[22] - Net cash flow from financing activities was RMB -114,361,075.58, compared to RMB 1,598,918,645.11 in the previous year[22] - The company's cash and cash equivalents at the end of the period stood at RMB 805,482,331.70, down from RMB 1,971,570,882.45[22] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2.41 billion, a year-on-year increase of 3.29%[3] - Shareholders' equity attributable to the listed company at the end of the reporting period was RMB 2.30 billion, a year-on-year increase of 3.95%[3] - Total assets increased to 2,407,873,095.43 yuan, up from 2,331,074,065.19 yuan in the previous period[16] - Total liabilities decreased to 112,362,683.46 yuan, down from 122,834,954.30 yuan in the previous period[17] - Shareholders' equity increased to 2,295,510,411.97 yuan, up from 2,208,239,110.89 yuan in the previous period[17] - Total non-current assets increased to 193,897,039.30 yuan, up from 184,935,085.18 yuan in the previous period[16] Shareholder Equity and Share Repurchase - The company repurchased 401,398 shares through centralized bidding, accounting for 0.50% of the total shares, with a total payment of 30.9679 million yuan[13] - Basic earnings per share for the third quarter were RMB 0.9028, a year-on-year increase of 13.92%[3] Changes in Financial Assets and Liabilities - The company's monetary funds decreased from 1,954,739,150.26 yuan at the end of 2023 to 805,489,331.70 yuan as of September 30, 2024[15] - The company's trading financial assets increased significantly from 82,419,132.42 yuan at the end of 2023 to 1,280,798,993.53 yuan as of September 30, 2024[15] - The company's accounts receivable decreased from 58,505,242.13 yuan at the end of 2023 to 47,756,747.38 yuan as of September 30, 2024[15] - The company's inventory increased from 46,800,372.11 yuan at the end of 2023 to 56,516,908.76 yuan as of September 30, 2024[15] - The company's prepayments increased from 2,165,488.47 yuan at the end of 2023 to 7,153,444.98 yuan as of September 30, 2024[15] - The company's other receivables increased slightly from 1,178,489.60 yuan at the end of 2023 to 1,258,629.78 yuan as of September 30, 2024[15] - The company's fixed assets increased from 90,992,259.67 yuan at the end of 2023 to 109,448,452.08 yuan as of September 30, 2024[15] - The company's construction in progress decreased from 67,917,872.68 yuan at the end of 2023 to 59,814,909.47 yuan as of September 30, 2024[15] - The company's total current assets increased from 2,146,138,980.01 yuan at the end of 2023 to 2,213,976,056.13 yuan as of September 30, 2024[15] Sales and Interest Income - Sales expenses rose to 41,923,488.07 yuan, compared to 37,424,561.20 yuan in the same period last year[19] - Interest income for the first three quarters of 2024 was 41,053,469.49 yuan, up from 19,662,304.43 yuan in the same period last year[19]
安杰思(688581) - 2024 Q3 - 季度财报
HANGZHOU AGS MEDICAL TECHNOLOGY CO. (688581)2024-10-24 09:34